Please assess the completion status of the following clinical trial:

Trial Title: Fecal Microbiota Transplantation in Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18, body mass index 20-30 kg/m²~* Able to provide signed and dated informed consent~* Patients with moderate to severe depression (as expressed by a Hamilton Depression Rating Scale (HAMD-17) \> 17)~* Treatment as usual for depression~* In- and outpatients at the UPK Basel~Exclusion Criteria:~* Patients with mild MDD (HAMD-17 \< 17)~* Comorbid psychiatric disturbances such as substance abuse disorder, bipolar disorder, schizophrenia, eating disorders.~* Current medical conditions such as acute infectious disease,~* Dietary restrictions (vegetarian, vegan, gluten-free, PEG/TPN feeding, and any kind of deviation from the UPK standard catering)~* Recent use of medications besides their anti-depressant medication (within 3 months, mainly antibiotics or probiotic consumption within last six weeks).~* Pregnancy (tested before both MRI scans using the AlereTM TestPack +Plus hCG Urine Test), breast-feeding~* Body Mass Index (BMI) \> 30~* Current or recent use of antibiotics (within 3 months before inclusion)~* Anticipated antibiotic use in upcoming 4 weeks~* Inability to read and understand the participant's information and informed consent form~* Inability (e.g. dysphagia) to or unwilling to swallow capsules~* Active vomiting~* Known or suspected toxic megacolon and/or known small bowel ileus~* Major gastrointestinal surgery (e.g. significant bowel resection) within 3 months before enrolment. This does not include appendectomy or cholecystectomy.~* History of total colectomy or bariatric surgery.~* Concurrent intensive induction chemotherapy, radiation therapy or biological treatment for active malignancy. Patients on maintenance chemotherapy may be enrolled only after consultation with a medical monitor.~* Life expectancy \< 6 months~* Patients with a history of severe anaphylactic or anaphylactoid food allergy~* Solid organ transplant recipients ≤ 90 days post-transplant or on active treatment for rejection~* Neuropenia (≤500 neutrophils/mL) or other severe immunosuppression. Anti-TNF will be permitted. Patients on monoclonal antibodies to B and T cells, glucocorticoids, antimetabolites (azathioprine, 6-mercaptopurine, methotrexate), calcineurin inhbitors (tacrolimus, cyclosporine) and mycophenolate mofetil may be enrolled only after consultation with the medical monitor.~* A condition that would jeopardize the safety or rights of the subject, would make it unlikely for the subject to complete the study, or would confound the results of the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- FMT group (Type: EXPERIMENTAL): Patient group receiving active FMT capsules
- Placebo group (Type: PLACEBO_COMPARATOR): Patient group receiving placebo capsules

Based on this trial design, predict the completion outcome and termination type (if applicable).